信達生物製藥

INNOVENT BIOLOGICS, INC.

(Incorporated in the Cayman Islands with Limited Liability)

(Stock Code: 1801)

VOLUNTARY ANNOUNCEMENT
MAZDUTIDE 9MG SUPPLEMENTARY APPLICATION ACCEPTED FOR REVIEW BY CHINA'S NATIONAL MEDICAL PRODUCTS ADMINISTRATION

This announcement is made by Innovent Biologics, Inc. (the "**Company**" or "**Innovent**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that the supplementary application for the 9mg dosage of mazdutide, an innovative glucagon ("**GCG**")/ glucagon-like peptide-1 ("**GLP-1**") dual receptor agonist, for the long-term weight management in adults with moderate to severe obesity has been accepted for review by the Center for Drug Evaluation ("**CDE**") of China's National Medical Products Administration ("**NMPA**"). This application of mazdutide 9mg aims to address a pressing unmet clinical need in China by offering a highly effective and safe new treatment option for adults with moderate-to-severe obesity, beyond current standard-of care metabolic and bariatric surgery.

This application is based on the encouraging results from the Phase 3 registration clinical study GLORY-2 (NCT06164873) of mazdutide 9mg in Chinese adults with moderate to severe obesity. The study recently met its primary endpoints and all key secondary endpoints.

- At week 60, participants in the mazdutide group exhibited continuous weight loss, with no plateau observed. The mazdutide 9mg group achieved a mean weight reduction of 18.55%, compared to 3.02% in the placebo group. 44.0% of participants in the mazdutide 9mg group achieved a weight reduction of 20% or more, versus 2.6% in the placebo group ($P<0.0001$ for all comparisons).

- The key secondary endpoints also demonstrated that mazdutide 9mg achieved a weight loss of up to 20.08% at week 60 among participants without type 2 diabetes ("**T2D**"), with the weight loss trend not yet reaching a plateau by the end of the study. Furthermore, nearly half (48.7%) of the non-diabetic participants achieved weight loss exceeding 20% (placebo: 3.1%; $P<0.0001$).

- Additionally, the study observed that mazdutide 9mg significantly reduced liver fat content, with a mean percent reduction from baseline of 71.9%, and demonstrated significant improvements in other key cardiometabolic endpoints, including blood pressure, blood lipids, and serum uric acid, as well as significant reduction in waist circumference.

- Mazdutide 9mg exhibited a favorable safety profile, with no new safety signals identified.

Detailed data from the GLORY-2 study, which met all its endpoints, are planned for disclosure at future international academic conferences or in scientific publications.

Mazdutide 9mg is currently the only GLP-1 receptor agonist that achieves over 20% weight loss in obese adults without T2D after 1 year of treatment with just a 2-step dose titration. Its development provides evidence-based medical support for effective weight management in Chinese patients with moderate-to-severe obesity, offering an alternative to metabolic surgery. The Company is delighted that the supplementary application for mazdutide 9mg has been accepted. Our strategic portfolio – ranging from 2mg-4mg-6mg targeting the broad overweight/obese population, to the 3mg-6mg-9mg dosage now targeting the severely obese population – is built upon profound scientific insight and clear market needs. It is designed to provide a 'stratified', personalized solution precisely tailored to the treatment goals and clinical needs of obese patients across the severity spectrum. The Company will work closely with regulatory agency, aiming to bring this novel therapeutic option to broad patient population.

About Mazdutide

Innovent entered into an exclusive license agreement with Eli Lilly and Company (Lilly) for the development and potential commercialization of mazdutide, a dual GCG/GLP-1 receptor agonist, in China. As a mammalian oxyntomodulin (OXM) analogue, in addition to the effects of GLP-1 receptor agonists on promoting insulin secretion, lowering blood glucose and reducing body weight, mazdutide may also increase energy expenditure and improve hepatic fat metabolism through the activation of glucagon receptor. Mazdutide has demonstrated excellent weight loss and glucose-lowering effects in clinical studies, as well as reducing waist circumference, blood lipids, blood pressure, serum uric acid, liver enzymes, liver fat content and improving insulin sensitivity.

Innovent is currently conducting or has completed seven Phase 3 clinical studies of mazdutide, including:

- GLORY-1: A Phase 3 clinical study conducted in Chinese adults with overweight of obesity;

- GLORY-2: A Phase 3 clinical study conducted in Chinese adults with moderately to severely obesity;

- DREAMS-1: A Phase 3 clinical study conducted in Chinese adults with untreated T2D;

- DREAMS-2: A Phase 3 clinical study comparing mazdutide versus dulaglutide in Chinese adults with T2D who have poor glycemia control with oral medication; and

- DREAMS-3: A Phase 3 clinical study comparing mazdutide versus semaglutide in Chinese adults with T2D and obesity;

- GLORY-3: A Phase 3 clinical study comparing mazdutide versus semaglutide in Chinese adults with overweight of obesity accompanied metabolic-associated fatty liver disease (MAFLD);

- GLORY-OSA: A Phase 3 trial in Chinese participants with obstructive sleep apnea (OSA) and obesity;

Among these, the first five Phase 3 clinical studies have all met their primary endpoints, while the remaining two Phase 3 clinical studies are still ongoing.

In addition, several clinical studies of mazdutide are ongoing in adolescents with obesity, patients with metabolic dysfunction-associated steatohepatitis (MASH), heart failure with preserved ejection fraction (HFpEF) etc.

Mazdutide has earned widespread recognition supported by robust data set. Its Phase 2 clinical trial in Chinese subjects with overweight or obesity was selected by *Nature Communications* as one of the 50 most important studies in translational and clinical research and highlighted as Editor's Choice. Additionally, mazdutide was listed among the "Top 10 Most Anticipated Drug Launches of 2025" by the FIERCE Pharma.

Furthermore, clinical findings on mazdutide have been featured in top-tier international journals such as *The New England Journal of Medicine*, *Nature Communications*, *Diabetes Care*, and *eClinicalMedicine*, as well as presented at leading scientific conferences including the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) annual meetings. Notably, mazdutide is the first innovative drug in China's endocrinology and metabolism field to have clinical results published in The New England Journal of Medicine, underscoring its significant clinical value.

Mazdutide has received NMPA approval for two indications:

First Indication: As an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial Body Mass Index (BMI) of:

- BMI $\geq$ 28 kg/m² (obesity); or
- BMI $\geq$ 24 kg/m² (overweight) in the presence of at least one weight-related comorbid condition (e.g., hyperglycemia, hypertension, dyslipidemia, fatty liver, or obstructive sleep apnea syndrome).

Second Indication: For glycemic control in adults with T2D.

Monotherapy:

For adults with T2D who have inadequate glycemic control despite diet and exercise interventions.

Combination Therapy:

For adults with T2D who still have poor glycemic control despite:

Diet and exercise, plus metformin and/or sulfonylureas; and

Diet and exercise, plus metformin and/or SGLT2 inhibitors (SGLT2i).

By Order of the Board
Innovent Biologics, Inc.
Dr. De-Chao Michael Yu
Chairman and Executive Director

Hong Kong, China
November 25, 2025

As at the date of this announcement, the Board comprises Dr. De-Chao Michael Yu as Chairman and executive Director and Mr. Ronald Hao Xi Ede and Ms. Qian Zhang as executive Directors, and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Mr. Gary Zieziula, Dr. Shun Lu, Mr. Shuyun Chen and Dr. Stephen A. Sherwin as independent non-executive Directors.